| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
K6PC-5 (1-10 μM; 24 hours) dose-dependently raises the levels of loricin and involucrin in normal human emergency response (NHEK) cells. K6PC-5 uses intracellular Ca2+ nutritional signaling to encourage the creation of new cells. Furthermore, c-Jun N-terminated division phosphorylation and p42/44 extracellular signal regulation are stimulated by K6PC-5 [1]. K6PC-5 (1–10 μM; 24 h) stimulates human fibroblasts and causes oscillations in the intracellular Ca2+ concentration ([Ca2+]i) in these cells [2]. In EA.hy926 cells infected with EBOV, K6PC-5 (10, 25, and 50 μM; 48 hours) dramatically decreased EBOV-induced infection. In cell supernatants, K6PC-5 dramatically lowers viral titers and, in a concentrated way, greatly lowers VP40 levels [3].]
|
|---|---|
| ln Vivo |
In an inherently aged hairless mouse (56 weeks old), 1% K6PC-5 was topically administered for 2 weeks. This K6PC-5 therapy greatly enhanced the number of cutaneous fibroblasts and collagen synthesis. Therefore, dermal thickness is also greatly raised in
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: Normal human epidermal keratinocytes (NHEK) Tested Concentrations: 1 μM, 5 μM, 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: Involucrin and loricin levels increased in a dose-dependent manner. Cell proliferation experiment [2] Cell Types: human fibroblasts Tested Concentrations: 1 μM, 5 μM, 10 μM Incubation Duration: 24 h Experimental Results: Dramatically promoted human fibroblast proliferation and procollagen production. |
| Animal Protocol |
Animal/Disease Models: Intrinsically aged hairless mice (56 weeks old) [2]
Doses: 1% (Vehicle (PEG:EtOH = 7:3)) Route of Administration: Topical application; [2 ]. twice (two times) daily for 2 weeks Experimental Results: Enhanced fibroblast proliferation, collagen production, and ultimately increased dermal thickness. |
| References |
|
| Molecular Formula |
C19H37NO4
|
|---|---|
| Molecular Weight |
343.508
|
| Exact Mass |
343.272
|
| CAS # |
756875-51-1
|
| PubChem CID |
11660192
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.812
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
24
|
| Complexity |
329
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
CGYVFCHCRBGGJG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H37NO4/c1-3-5-7-9-11-13-18(23)17(12-10-8-6-4-2)19(24)20-16(14-21)15-22/h16-17,21-22H,3-15H2,1-2H3,(H,20,24)
|
| Chemical Name |
N-(1,3-dihydroxypropan-2-yl)-2-hexyl-3-oxodecanamide
|
| Synonyms |
K6PC5 K6PC 5 K6PC-5
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~291.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9111 mL | 14.5556 mL | 29.1112 mL | |
| 5 mM | 0.5822 mL | 2.9111 mL | 5.8222 mL | |
| 10 mM | 0.2911 mL | 1.4556 mL | 2.9111 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
